The pregnenolone-derivative MAP4343 as a new therapy for the treatment of depressive disorders: a preclinical project
Current antidepressant treatments are inadequate to rescue the brain structural alterations reported in depressed individuals. MAP4343 is an innovative neuronal plasticity modulator showing potential antidepressant efficacy. DEPSTER will validate the use MAP4343 as a novel therapy for depression.
2 170 850.00€
Pharmaceutical Products / Drugs